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We evaluated that early metabolic response determined by 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (FDG-PET/CT) during radiotherapy (RT), pre-
dicts outcomes in non-small cell lung cancer.
Material and methods
Twenty-eight patients evaluated using pretreatment 18F-FDG-PET/CT (PETpre) and interim
18F-FDG-PET/CT (PETinterim) after 11 fractions of RT were retrospectively reviewed. Maxi-
mum standardized uptake value (SUVmax) was calculated for primary lesion. Predictive
value of gross tumor volume (ΔGTV) and SUVmax (ΔSUVmax) changes was evaluated
for locoregional control (LRC), distant failure (DF), and overall survival (OS). Metabolic
responders were patients with ΔSUVmax >40%.
Results
Metabolic responders showed better trends in 1-year LRC (90.9%) than non-responders
(47.1%) (p = 0.086). Patients with large GTVpre (�120 cc) demonstrated poor LRC (hazard
ratio 4.14, p = 0.022), while metabolic non-responders with small GTVpre (<120 cc) and
metabolic responders with large GTVpre both had 1-year LRC rates of 75.0%. Reduction of
25% in GTV was not associated with LRC; however, metabolic responders without a GTV
response showed better 1-year LRC (83.3%) than metabolic non-responders with a reduc-
tion in GTV (42.9%). Metabolic responders showed lower 1-year DF (16.7%) than non-
responders (50.0%) (p = 0.025). An ΔSUVmax threshold of 40% yielded accuracy of 64% for
predicting LRC, 75% for DF, and 54% for OS. However, ΔGTV > 25% demonstrated inferior
diagnostic values than metabolic response.
Conclusions
Changes in tumor metabolism diagnosed using PETinterim during RT better predicted treat-
ment responses, recurrences, and prognosis than other factors historically used.
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Background
Fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) imaging has become
an important and popular tool for determining the disease stage in patients with non-small-
cell lung cancer (NSCLC). The National Comprehensive Cancer Network recommends the
use of 18F-FDG-PET/computed tomography (CT) for the appropriate staging of lung cancer
[1].
There are several roles of FDG-PET/CT in NSCLC, such as diagnosis, prognosis, and radio-
therapy (RT) planning. Recent investigations have shown that FDG-PET/CT has more than
90% accuracy in diagnosis of malignant nodules, with a low false-positive rate [2]. FDG-PET
also plays a significant role in nodal staging (accuracy 90%, sensitivity 79–85%, and specificity
87–92%) [3, 4] and distant metastasis detection, with previously unsuspected diagnosis of
extrathoracic lesions in up to 10% of patients, beyond CT alone [5]. FDG-PET offers a benefit
over conventional CT after treatment where, for example, although tumor shrinkage may be
observed, inflammation and fibrosis after neoadjuvant chemotherapy or RT make assessment
difficult [1].
In addition, FDG-PET plays an important role in target volume delineation of the gross
tumor volume (GTV), for both the primary tumor and lymph nodes [6]. Its superior contrast
between tumor and non-tumor tissue means that FDG-PET can also decrease inter-physician
contouring variability, compared to delineation with CT alone [7]. It also greatly assists physi-
cians in distinguishing the tumor tissue from atelectasis [8]. Therefore, a consensus report has
been endorsed for target volume delineation using PET imaging [9].
Currently, chemoradiotherapy (sequential or concurrent) is considered as a standard treat-
ment for locally advanced NSCLC. Despite the emergence of immunotherapy, targeted ther-
apy, and new RT techniques, the prognosis of those patients remains poor. Therefore, the
ability to identify non-responders during treatment, in order to change ineffective treatment
early on, is very desirable [10]. Several studies have demonstrated interim PET (PETinterim)
metrics as a prognostic factor, but most of these included conventional three-dimensional con-
formal RT and various chemotherapy regimens, with varied timing of PETinterim. Therefore,
in this study, we focused on metabolic and volumetric parameters, which are easily accessible
during RT, in patients treated with modern RT and certain chemotherapy regimens.
Materials and methods
Study population
Patients diagnosed with NSCLC who had undergone RT with PETinterim between March 2015
and January 2018 were enrolled. Patients were excluded if they underwent RT with preopera-
tive aim (n = 7), if pre-RT FDG-PET/CT (PETpre) was not available or was performed at
another institution (n = 6), if they did not complete RT (n = 2), and if follow-up details were
missing (n = 4). Ultimately, we retrospectively reviewed medical records and tumor character-
istics of 28 patients, as well as their clinical outcomes. This study was approved by the Health
Institutional Review Board of Yonsei University Hospital (No. 4-2019-0608). The study was
conducted in accordance with the provisions of the 1975 Declaration of Helsinki. The require-
ment for informed consent was waived owing to the retrospective nature of this study. All data
between March 2015 and May 2019 were fully anonymized before authors accessed them.
Treatment
All patients, except three patients who were medically ineligible due to poor performance and
comorbidity, received chemotherapy using a platinum- and taxane-based regimen. Twenty-
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five patients began on RT administered concurrently with weekly paclitaxel (45 mg per square
meter of body-surface area) via intravenous infusion over 1 hour, followed by carboplatin at
an area under the plasma concentration time curve (AUC) of 2 mg/mL � minute, with a total
dose of AUC � (glomerular filtration rate + 25), as an intravenous infusion over 30 minutes.
All patients underwent simulation four-dimensional CT without contrast enhancement
(3-mm slice thickness) for RT planning in both initial plan and interim adaptive plan. The
GTV was delineated by single radiation oncology expert with more than 30 year experience
in lung cancer (C.G.L) at simulation CT with contrast enhancement, including the primary
tumor and involved regional nodes (1 cm or larger in short axis, showing abnormal FDG-avid-
ity on PETpre, or proven on biopsy), based on both CT and pre-RT FDG-PET/CT. The internal
GTV was contoured on all-phase four-dimensional CT scans in order to reflect the effects of
respiration. The clinical target volume was defined as GTV plus a 3-5-mm margin in order to
include microscopic tumor extension. An additional 3-mm margin to both the internal GTV
and clinical target volume was added to planning target volume (PTV1 and PTV2, respec-
tively) based on institutional image-guidance strategies. A simultaneous integrated boost was
utilized in PTV1 for 63 Gy in 30 fractions and PTV2 for 54 Gy in 30 fractions. All patients
were treated with intensity-modulated RT using volumetric-modulated arc therapy (Elekta
VMAT, Elekta, Stockholm, Sweden) [11]. Daily pretreatment imaging using kilovoltage cone-
beam CT was performed for image-guided RT.
18F-FDG-PET/CT method
All PETpre and PETinterim scans were performed using Discovery STE (GE Healthcare, Mil-
waukee, WI, USA) scanner. Every patient fasted for a minimum of 6 hours before 18F-FDG
administration, ensuring a blood glucose level below 140 mg/dL. Patients were then injected
with FDG at 5.5 MBq/kg. After allowing 45–60 minutes for tracer uptake, patients underwent
PET/CT imaging along with a non-contrast low-dose CT scan for attenuation correction (30
mA, 140 kVp). Images were acquired from the base of the skull to the proximal thigh, with
acquisition times of 3 minutes/bed position. The intrinsic spatial resolution of the system was
approximately 5 mm (full width at half maximum) in the center of the field of view. All PET
images were then reconstructed using a three-dimensional row-action maximum likelihood
interactive reconstruction algorithm. All patients started RT median 16.5 days (range, 8–35
days) after the PETpre scan to accurately reflect the tumor metabolism.(9) To minimize inter-
pretation difficulty due to non-specific FDG accumulation from radiation-induced inflamma-
tion during RT, we performed a PETinterim scan at a median of 2 weeks (range 13–22 days)
after initiation of RT [12].
PET metrics
PET/CT images were consistently analyzed by two radiation oncology physicians (N.K. and
C.G.L.) using the MIM Maestro 6.7 (MIM Software Inc., Cleveland, OH, USA). The region of
interest was delineated over the primary tumor on the PETpre and PETinterim scans using PET
Edge, a semi-automatic gradient-based method validated for its superiority over manual or
threshold methods [13]. This algorithm sets the contour boundary at the location where
the signal gradient is highest. Then, deformable registration of delineated GTV in contrast-
enhanced planning CT scans for initial and adaptive plan was performed to adjust the region
of interest generated by two blinded radiation oncologists. Final region of interest for further
analysis regarding PET parameter was approved by single radiation oncologist (C.G.L.). The
SUV was measured in all voxels in the primary tumor region of interest. The maximum SUV
(SUVmax) was defined as the maximum decay-corrected activity concentration in the tumor/
PLOS ONE Predictive value of interim 18F-FDG-PET in NSCLC
PLOS ONE | https://doi.org/10.1371/journal.pone.0236350 July 20, 2020 3 / 13
(injected dose/body weight). Since metabolic target volume or total lesion glycolysis is based
on relative uncertainty compared to maximum value of SUV due to inflammation, fibrosis, or
atelectasis in lung cancer, we only analyzed the SUVmax in the current study.
Statistical analysis
The percentage change in each parameter between the PETpre and PETinterim was calculated
using the following equation [14]:
D½Parameter� ¼ f½Parameterpre   Parameterinterim�=Parameterpreg � 100%
Since there is limited information for universally accepted the optimal cut-off value for
dynamics in PET parameters, receiver operating characteristics curve analyses regarding any
failures were used to assess the cut-off threshold of SUVmax from PETinterim for identifying
metabolic responders. As a reference, volumetric response was assessed based on GTV changes
(ΔGTV), with a threshold of 25%, which could improve the response assessment compared to
Response Evaluation Criteria in Solid Tumors [15]. Locoregional recurrence (LRR) and dis-
tant failures (DF) were defined as any first recurrence within and outside the PTV until the
last follow-up, respectively. Overall survival (OS) was calculated from the day of first RT to the
date of death or the last follow-up visit. Survival curves were estimated using the Kaplan-Meier
method and compared using the log-rank test. Univariable analysis of LRR and DF was per-
formed using Cox regression analysis. A multivariable analysis was not performed because no
statistically significant factors were identified on univariable analysis. Sensitivity, specificity,
accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated
to assess the diagnostic value of selected parameters. In addition, Delong’s test after bootstrap-
ping 200 times was performed to compare the predictive value of selected cutoff values from
parameters. The α level of 0.05 was used: a p-value <0.05 was regarded as a rejection to the
null hypothesis and therefore considered statistically significant. All statistical analyses were
performed using SPSS version 25.0.0 (IBM Corp., Armonk, NY) and R (version 3.6.3; R Foun-
dation for Statistical Computing, Vienna, Austria).
Results
Cohort characteristics
Details of the patients’ characteristics are presented in Table 1. Males predominated (92.9%)
among the entire group of 28 patients, and the median age was 73.5 years (interquartile range
(IQR) 66.0–88.0). Most patients were diagnosed as having squamous cell carcinoma (64.3%),
followed by adenocarcinoma (35.7%). Median primary tumor size was 4.1 cm (IQR 3.4–5.3)
and more than half of the patients (82.2%) were diagnosed at stage III. The PETinterim was
obtained approximately 11 fractions after treatment initiation, with a median dose of 23.1 Gy
(IQR 23.1–24.7).
Changes during RT
The median GTVpre and SUVmax(pre) were 119.6 cc (IQR 85.7–190.6) and 15.5 (IQR 11.5–
21.4), respectively. Both GTV and SUVmax were generally decreased on PETinterim; median
ΔGTV and ΔSUVmax were 23.6% (IQR 14.0–49.6%) and 32.9% (IQR 8.4–64.6%), respectively.
However, four patients showed an increased GTV and another five showed increased SUVmax.
The quantitative analysis of SUVmax and GTV is summarized in S1 Table.
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Treatment outcomes
Median follow-up was 17.7 months (IQR 11.9–22.2). Twelve patients developed LRR, 15
patients showed DF, and 7 patients experienced both LRR and DF; 4 of them encountered
with simultaneous LRR and DF as a first treatment failure. The overall 1-year LRR rate was
34.3%, while the DF rate was 36.1% for the entire cohort (S1A Fig). One-year OS and progres-
sion-free survival rates were 82.0% and 53.3%, respectively (S1B Fig).
Prognostic factors for treatment outcomes
With an area under the receiver operating characteristics curve of 0.812 for any failures (S2
Table), a threshold of 40% was calculated as the optimal cut-off for ΔSUVmax. With this thresh-
old, there were 12 metabolic responders and 16 non-responders. Metabolic response based on
ΔSUVmax of 40% demonstrated a difference in locoregional control (LRC), but this was not
statistically significant for the entire cohort; 1-year LRC rate for metabolic responders (n = 12)
was 90.9%, compared to 47.1% for non-responders (n = 16, Fig 1A, Table 2). However, large
GTVpre (�120 cc) was identified as a poor prognostic factor for LRC on univariable analysis
(HR 4.14, 95% CI 1.23–13.97; p = 0.022), whereas ΔGTV had little impact on LRC (p = 0.341).
However, metabolic response showed a borderline impact on LRC, along with GTVpre
Table 1. Patient and treatment characteristics.
Patient characteristics N %








Squamous cell carcinoma 18 64.3
Adenocarcinoma 10 35.7
Primary tumor size (cm, median [IQR]) 4.1 [3.4–5.3]
�4 cm 17 60.7




Treatment characteristics N %
Aim
Definitive 28 100.0
Concurrent chemotherapy 25 89.3
Intensity-modulated radiation therapy 28 100.0
Median total dose (Gy, median [IQR]) 63 [61.5–63.0]
Median fraction dose (Gy, median [IQR]) 2.1 [2.1–2.2]
Fractions of RT completed before interim PET (fractions, median [range]) 11 [10–14]
Dose of RT completed before interim PET (Gy, median [range]) 23.1 [23.1–24.7]
Abbreviations: IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance status; RT,
radiation therapy
https://doi.org/10.1371/journal.pone.0236350.t001
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(Fig 1B). Metabolic responders with a small GTVpre (n = 4) showed the best 1-year LRC rate,
of 100%. In contrast, metabolic non-responders with a large GTVpre (n = 8) showed the worst
1-year LRC rate, of 15%. There was no difference in LRC between metabolic non-responders
with a small GTVpre (n = 8) and metabolic responders with a large GTVpre (n = 8) (1-year LRC
rate 75.0% vs. 75%, p = 0.584).
Fig 1. Locoregional control rate according to the SUVmax change: A—according to the SUVmax reduction rate, and
B—stratified by pretreatment GTV (GTVpre). Responders were patients with SUVmax reduction rates�40%,
whereas non-responders were those with SUVmax reduction rates<40%.
https://doi.org/10.1371/journal.pone.0236350.g001
Table 2. Predictors of locoregional recurrence identified using a Cox proportional hazards model.
1-yr LRC Univariable analysis
% HR 95% CI p-value
Age (yrs) <70 57.1 ref
�70 70.6 0.51 0.16–1.6 0.252
Pathology Adenoca 57.1 ref
SqCCa 70.6 0.61 0.19–1.92 0.395
Size <4 cm 77.8 ref
�4 cm 58.8 1.31 0.39–4.38 0.659
T T1-2 64.6 ref
T3-4 66.7 0.64 0.19–2.15 0.473
Stage I-II 50.0 ref
III 68.3 0.84 0.18–3.87 0.819
Total dose <60 Gy 0.0 ref
�60 Gy 68.1 0.18 0.02–1.79 0.145
GTVpre <120 cc 86.7 ref
�120 cc 37.0 4.14 1.23–13.97 0.022
SUVmax(pre) <15 50.8 ref
�15 78.6 0.97 0.9–1.05 0.447
GTVpre−GTVint (+) 88.9 ref
(-) 42.9 1.39 0.22–4.28 0.093
SUVmax(pre)−SUVmax(int) (+) 67.1 ref
(-) 60.0 0.77 0.16–3.67 0.747
ΔGTV � 25% 71.8 ref
< 25% 58.3 0.57 0.18–1.81 0.341
ΔSUVmax � 40% 90.9 ref
< 40% 47.1 3.02 0.8–11.32 0.101
Abbreviations: yr, year; LRC, locoregional control rate; HR, hazard ratio; CI, confidence interval; Adenoca, adenocarcinoma; SqCCa, squamous cell carcinoma; Gy, gray;
GTV, gross tumor volume; SUVmax, maximum standardized uptake value; Xpre, pre-treatment value; Xint, interim value
https://doi.org/10.1371/journal.pone.0236350.t002
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Patients with a favorable metabolic response showed better 1-year DF-free rate than non-
responders: 83.3% for good responders and 50.0% for non-responders (p = 0.025) (Fig 2A,
Table 3). However, GTVpre, SUVmax(pre), and ΔGTV were not associated with DF. Metabolic
responders showed prolonged survival than non-responders, but this was not statistically
Fig 2. Clinical outcomes according to reduction in SUVmax: A—Distant failure-free rate of patients, and B—
overall survival rate. Responders were patients with SUVmax reduction rates�40%, whereas non-responders were
those with SUVmax reduction rates<40%.
https://doi.org/10.1371/journal.pone.0236350.g002
Table 3. Predictors of distant failures identified using a Cox proportional hazards model.
1-yr DFFR Univariable analysis
% HR 95% CI p-value
Age (yrs) <70 50.0 ref
�70 72.2 0.77 0.27–2.19 0.626
Pathology Adenoca 60.0 ref
SqCCa 72.2 0.87 0.30–2.50 0.800
Size <4 cm 53.0 ref
�4 cm 70.6 0.5 0.17–1.50 0.219
T T1-2 56.3 ref
T3-4 75.0 0.66 0.22–1.94 0.450
Stage I-II 40.0 ref
III 69.0 0.57 0.18–1.83 0.349
Total dose <60 Gy 50.0 ref
�60 Gy 64.9 0.67 0.09–5.27 0.705
GTVpre <120 cc 61.9 ref
�120 cc 66.7 1 1.00–1.01 0.249
SUVmax(pre) <15 61.5 ref
�15 66.0 0.98 0.91–1.05 0.490
GTVpre−GTVint (+) 62.2 ref
(-) 75.0 0.54 0.07–4.19 0.556
SUVmax(pre)−SUVmax(int) (+) 64.6 ref
(-) 60.0 1.68 0.56–5.06 0.355
ΔGTV � 25% 61.5 ref
< 25% 65.2 0.62 0.22–1.74 0.368
ΔSUVmax � 40% 83.3 ref
< 40% 50.0 3.93 1.09–14.15 0.036
Abbreviations: yr, year; DFFR, distant failure free rate; HR, hazard ratio; CI, confidence interval; Adenoca, adenocarcinoma; SqCCa, squamous cell carcinoma; Gy, gray;
GTV, gross tumor volume; SUVmax, maximum standardized uptake value; Xpre, pre-treatment value; Xint, interim value
https://doi.org/10.1371/journal.pone.0236350.t003
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significant (1-year OS rate 91.7% vs. 74.5%, p = 0.449) (Fig 2B). No statistically significant
prognostic factor was found to influence OS (S3 Table).
Diagnostic tests
The diagnostic test results are presented in Table 4. Using the threshold of 40%, ΔSUVmax pro-
vided a sensitivity of 56.3%, specificity of 75.0%, accuracy of 64.3%, PPV of 75.0%, and NPV
of 56.3% for predicting LRR. GTVpre with a threshold of 120 cc was identified as a tool for pre-
dicting LRR, with a diagnostic accuracy of 71.4%. ΔSUVmax showed better diagnostic ability
for predicting DF than GTVpre, with a sensitivity, specificity, and accuracy of 75.0%; PPV of
80.0%; and NPV of 69.2%. There was no statistical difference in AUC value for LRR between
ΔSUVmax and GTVpre criteria (0.656 and 0.708, p = 0.681, S2 Fig). The AUC was 0.766 and
0.603 for DF based on ΔSUVmax and GTVpre criteria, respectively (p = 0.043, S2 Fig).
Discussion
In this study, we investigated the predictive value of using 18F-FDG-PET parameters before
and during RT for predicting treatment outcomes in patients with NSCLC. Although there
was a significant difference in LRC according to GTVpre, metabolic response showed some
degree of impact based on subgroup analysis. However, changes in SUVmax were signifi-
cantly associated with DF, and this criterion has proved its diagnostic value to predict
response to RT.
Tumor burden, measured by GTV, is important in tumor control models of RT; a given
dose induces a log cell kill, assuming that the larger the tumor, the more cells and, therefore,
the more radiation needed for LRC [16]. Given that GTVpre defined on CT was significantly
associated with LRR at the RT dose (total dose of 60–63 Gy) used in the present study, it can
be assumed that dose escalation is needed to achieve local control in NSCLC [17]. Secondary
Table 4. Diagnostic tests for response criteria based on ΔSUVmax and GTVpre.
Locoregional recurrence Distant failure Overall survival
Value 95% CI Value 95% CI Value 95% CI
ΔSUVmax (40%)
Sensitivity 56.3 (31.9–80.6) 75.0 (53.8–96.2) 43.8 (19.4–68.1)
Specificity 75.0 (50.5–99.5) 75.0 (50.5–99.5) 66.7 (40–93.3)
False-positive rate 25.0 (5.0–49.5) 25.0 (0.5–49.5) 33.3 (6.7–60)
False-negative rate 43.8 (19.4–68.1) 25.0 (3.8–46.2) 56.3 (31.9–80.6)
Diagnostic accuracy 64.3 (46.5–82) 75.0 (59–91) 53.6 (35.1–72)
PPV 75.0 (50.5–99.5) 80.0 (59.8–100.2) 63.6 (35.2–92.1)
NPV 56.3 (31.9–80.6) 69.2 (44.1–94.3) 47.1 (23.3–70.8)
GTVpre (120cc)
Sensitivity 66.7 (40–93.3) 41.7 (13.8–69.6) 58.3 (30.4–86.2)
Specificity 75.0 (53.8–96.2) 37.5 (13.8–61.2) 75.0 (53.8–96.2)
False-positive rate 25.0 (3.8–46.2) 62.5 (38.8–86.2) 25.0 (3.8–46.2)
False-negative rate 33.3 (6.7–60) 58.3 (30.4–86.2) 41.7 (13.8–69.6)
Diagnostic accuracy 71.4 (54.7–88.2) 39.3 (21.2–57.4) 67.9 (50.6–85.2)
PPV 66.7 (40–93.3) 33.3 (9.5–57.2) 63.6 (35.2–92.1)
NPV 75.0 (53.8–96.2) 46.2 (19.1–73.3) 70.6 (48.9–92.3)
Abbreviations: CI, confidence interval; SUVmax, maximum standardized uptake value; GTV, gross tumor volume; PPV, positive predictive value; NPV, negative
predictive value.
https://doi.org/10.1371/journal.pone.0236350.t004
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analysis of the RTOG 9311 study revealed that increasing GTV (>45 cm3) was related to poor
OS and progression-free survival [18]. Several other series [19, 20] have also suggested that
tumor volume is a significant prognostic factor for survival. However, a recent prospective,
observational factor study of TROG 99.05 [21] found that a large primary tumor volume was
not associated with poor survival, after adjusting for the effects of T and N stage. Instead, large
primary tumor volume had an adverse impact on survival only within the first 18 months
(comparable to the median follow-up period for the present study). In addition, changes in
GTV had no impact on the treatment outcomes, and metabolic response could help stratify
patients: those with a large GTVpre and favorable metabolic response showed an LRC rate
comparable to that of patients with a small GTVpre and poor metabolic response. Several series
provide evidence for a correlation between SUV and tumor cell proliferation [22]. An early
reduction in FDG uptake during treatment can predict tumor response. In addition, SUVmax
represents the enhanced tapping of 18F-FDG into the tumor cells, due to biological mecha-
nisms, tumor aggressiveness, and hypoxia [23].
Owing to the heterogeneity of patient populations with NSCLC at an advanced stage, there
is no concrete evidence regarding the prognostic value of PETpre. A recent meta-analysis of 13
studies with 1474 patients demonstrated that high SUVmax(pre) in the primary tumor was asso-
ciated with reduced survival [24]. Another meta-analysis of 36 studies on 5807 patients with
surgically treated NSCLC also identified SUVmax(pre) as a prognostic factor for disease-free sur-
vival, with an HR of 1.52 (95% CI 1.16–2.00). However, the retrospective study by Hoang et al.
[25] with a homogeneous population did not find a correlation between metabolic parameters
on PETpre and survival, which is consistent with the findings of the present study.
Discriminating non-responders from responders can help physicians to avoid unnecessary
toxicity in patients expected to have a poor prognosis, by early interruption of ineffective ther-
apy. Because changes in FDG uptake were associated with tumor shrinkage, PETinterim can
also help physicians decide when to modify the RT plan, with PTV modification or dose esca-
lation. Several series with various sample sizes (10–77 patients) have shown the prognostic
value of PETinterim in patients with NSCLC treated with RT [26, 27] and in those with other
solid tumors [28, 29]. And secondary analysis of ESPATUE study revealed that remaining
SUVmax in the primary tumor after induction chemotherapy was associated with survival and
freedom from extracranial progression in consistent to the current study [30]. Furthermore, a
recent meta-analysis of 21 studies on 627 patients reported PETinterim as a promising tool for
the early judgment of treatment [12]. However, because most of these studies were retrospec-
tive and examined multiple outcomes, concerns around the statistics include the fact that there
were multiple comparisons and selective reporting of endpoints. More importantly, definite
criteria or standard parameters have not yet been determined, and prognostic metrics range
from SUVmax [27] and ΔSUVmax [31] to total lesion glycolysis [32] and metabolic tumor vol-
ume [14]. In our series, ΔSUVmax was associated with DF and LRR, suggesting that this param-
eter helps to stratify patients. Metabolic response based on ΔSUVmax was not significantly
associated with LRC on univariable analysis, possibly due to the lack of statistical power.
However, SUV as a semiquantitative index has limitations owing to poor reproducibility
[24], making it difficult to adopt a threshold among different centers. In place of the SUV
value itself, we calculated a cut-off value for ΔSUVmax (a 40% reduction), which was predictive
of both LRR and DF. Criteria for the relative change in SUVmax can be a tool for predicting
early treatment response in the same institution, which, in turn, can minimize the issue of vari-
ability and enhance the prognostic value of this metabolic parameter.
Early response appears to be an indicator of tumor biology and a predictor of the likelihood
of treatment failure. Thus, the assessment of early response makes it easier to identify poor
responders who are eligible for the intensification or modification of treatment, instead of
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continuation of the initial treatment (the so-called 18F-FDG-PET/CT-guided treatment algo-
rithm). A recent phase II trial proved that adaptive RT with escalated doses accompanied by
PETinterim is feasible and results in favorable LRC [33]. A further ongoing clinical trial (RTOG
1106) is examining adaptive RT with dose escalation for FDG-avid tumors on PETinterim.
Another promising area of research that needs further prospective trials is the early switching
of systemic chemotherapy in patients with a small decrease in SUVmax. Recently, there are sev-
eral on-going trials in other solid tumors investigating the role of immune checkpoint block-
ade stratified by PET parameters (NCT 03829007, NCT 03853187, NCT 02760225).
Our study had several limitations. First, as a retrospective analysis, the results should be
interpreted with caution. Although we have analyzed an optimal cut-off value for SUVmax, we
used a median value of GTV and 25% criteria for ΔGTV as previously reported to minimize
statistical overfitting. Optimal threshold could be derived from further investigation with large
number of patients and it should be externally validated. Second, there are inherent biases
since this study was carried out in a single institution. However, our analysis was strengthened
using consistent modern 18F-FDG-PET/CT, imaging analyses, chemotherapy regimen, and
RT techniques. Other limiting factors include possible inflammatory changes caused by irradi-
ation, which may mimic changes in tumor glucose metabolism associated with treatment.
We evaluated the PETinterim at 2 weeks after initiation of RT to minimize the overlapping of
inflammation and residual tumor [12]. In addition, there is a possibility of overestimation of
changes in SUV, because of the partial-volume effect; tumor reduction may underestimate the
FDG uptake. Lastly, lack of a univocal parameter remains a challenge in dealing with the meta-
bolic parameters as a universal prognostic or predictive factor. Although FDG uptake is gener-
ally used as a parameter to reflect the proportion of viable tumor cells, new tracers are now
available for specifically detecting apoptosis and proliferation to provide a highly accurate pre-
diction of treatment response.
Conclusions
We could cautiously assume that response criteria based on changes in SUVmax during RT
could be useful for identifying responders to current treatment among patients with NSCLC.
The optimal management of poor responders identified on PETinterim remains to be deter-
mined. Furthermore, a prospective study to confirm the efficacy of 18F-FDG-PET/CT-guided
algorithms in patients with NSCLC is warranted.
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